Prevalence and Study-Level Predictors of Chronic Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis
Ryan S D’Souza, Savannah Whitfield, Nasir Hussain, Anuj Bhatia, Dylan W Banks, Jason Parmar, Johana Klasova, Evan Mizerak, Larry J Prokop, Yeng F Her · 2026
Read Prevalence and Study-Level Predictors of Chronic Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis by Ryan S D’Souza, Savannah Whitfield, Nasir Hussain, Anuj Bhatia, Dylan W Banks, Jason Parmar, Johana Klasova, Evan Mizerak, Larry J Prokop, Yeng F Her (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13552395.txt.
Description
D'Souza and co-authors pool world data on lasting nerve damage caused by chemotherapy. The damage, felt as pain, numbness, or tingling in hands and feet, can linger long after treatment ends. Their 2026 review gathers 197 studies from 36 countries, covering nearly 73,000 patients, of whom about 26,000 had lasting nerve damage.
Across the pool, about forty-five percent of patients had nerve damage lasting at least three months past treatment. Rates ran highest in the first year after chemotherapy, then settled near forty percent beyond two years. Rates also varied by region, drug class, and cancer type. The authors urge targeted watching and prevention for high-risk groups. They frame lasting nerve damage as a major burden for cancer survivors.
Catalog record
| CREATOR | Ryan S D’Souza, Savannah Whitfield, Nasir Hussain, Anuj Bhatia, Dylan W Banks, Jason Parmar, Johana Klasova, Evan Mizerak, Larry J Prokop, Yeng F Her |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |